Bank of America Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces $36 Price Target

Bank of America analyst Brian Cheng initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy rating and a $36 price target.

Benzinga · 12/19/2019 15:23

Bank of America analyst Brian Cheng initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy rating and a $36 price target.